Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
First Claim
Patent Images
1. A pharmaceutical composition comprising a synthetic, modified oligonucleotide of 10 to 30 nucleotides in length comprising at least one modification wherein the at least one modification is selected from:
- at least one modified sugar moiety;
at least one modified internucleotide linkage;
at least one modified nucleotide, and combinations thereof;
wherein said oligonucleotide is an antisense compound which is 100% complementary to and specifically hybridizes to a complementary region of a natural antisense polynucleotide of a Reprogramming Factor gene selected from SEQ ID NOS;
4 or 5 and upregulates the function and/or expression of the Reprogramming factor gene in vivo or in vitro as compared to a normal control and a pharmaceutically acceptable excipient.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Reprogramming factor, in particular, by targeting natural antisense polynucleotides of a Reprogramming factor. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Reprogramming factors.
-
Citations
10 Claims
-
1. A pharmaceutical composition comprising a synthetic, modified oligonucleotide of 10 to 30 nucleotides in length comprising at least one modification wherein the at least one modification is selected from:
- at least one modified sugar moiety;
at least one modified internucleotide linkage;
at least one modified nucleotide, and combinations thereof;
wherein said oligonucleotide is an antisense compound which is 100% complementary to and specifically hybridizes to a complementary region of a natural antisense polynucleotide of a Reprogramming Factor gene selected from SEQ ID NOS;
4 or 5 and upregulates the function and/or expression of the Reprogramming factor gene in vivo or in vitro as compared to a normal control and a pharmaceutically acceptable excipient. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10)
- at least one modified sugar moiety;
Specification